LONDON, ENGLAND / ACCESSWIRE / May 4, 2016 / GW Pharmaceuticals plc (NASDAQ: GWPH) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Thursday, May 5, 2016 at 9:00 AM Eastern Time.

You can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=174974 or on the GW Pharmaceuticals website (www.gwpharm.com).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.gwpharm.com.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

SOURCE: Investor Calendar